A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastro-oesophageal reflux disease.
about
Negative Allosteric Modulators of Metabotropic Glutamate Receptors Subtype 5 in Addiction: a Therapeutic WindowAllosteric modulation of metabotropic glutamate receptors.Metabotropic glutamate receptors: from the workbench to the bedside.(3-Cyano-5-fluorophenyl)biaryl negative allosteric modulators of mGlu(5): Discovery of a new tool compound with activity in the OSS mouse model of addictionTreatment of GORD: Three decades of progress and disappointmentsCognitive effects of Group I metabotropic glutamate receptor ligands in the context of drug addiction.3-Cyano-5-fluoro-N-arylbenzamides as negative allosteric modulators of mGlu(5): Identification of easily prepared tool compounds with CNS exposure in rats.Development of allosteric modulators of GPCRs for treatment of CNS disordersMolecular Insights into Metabotropic Glutamate Receptor Allosteric ModulationMetabotropic glutamate receptors as novel therapeutic targets on visceral sensory pathways.Recent advances in the design and development of novel negative allosteric modulators of mGlu(5)Differential Modulation of Thresholds for Intracranial Self-Stimulation by mGlu5 Positive and Negative Allosteric Modulators: Implications for Effects on Drug Self-Administration.Self-injurious behaviour in intellectual disability syndromes: evidence for aberrant pain signalling as a contributing factor.Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discoverymGlu receptors and drug addiction.Evolving drugs in gastroesophageal reflux disease: pharmacologic treatment beyond proton pump inhibitors.Allosteric modulation of metabotropic glutamate receptors: structural insights and therapeutic potential.Review article: the clinical relevance of transient lower oesophageal sphincter relaxations in gastro-oesophageal reflux disease.Metabotropic glutamate receptors as targets for analgesia: antagonism, activation, and allosteric modulation.Pharmaceutical principles of acid inhibitors: unmet needs.Gastroesophageal reflux disease--from reflux episodes to mucosal inflammation.Therapeutic options for refractory gastroesophageal reflux disease.Evolving pharmacological approaches in gastroesophageal reflux disease.Recent progress on the identification of metabotropic glutamate 4 receptor ligands and their potential utility as CNS therapeutics.Novel therapeutics for gastro-esophageal reflux symptoms.mGlu5 negative allosteric modulators: a patent review (2010-2012).Current pharmacological management of gastroesophageal reflux disease.Therapeutic potential of targeting glutamate receptors in Parkinson's disease.The relevance of transient lower oesophageal sphincter relaxations in the pathophysiology and treatment of GORD.Localization and role of metabotropic glutamate receptors subtype 5 in the gastrointestinal tract.Gastro-oesophageal reflux disease: beyond proton pump inhibitor therapy.Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5.Discovery of VU0409106: A negative allosteric modulator of mGlu5 with activity in a mouse model of anxietymGlu5 Receptor Functional Interactions and AddictionEmerging Medical Therapies for the Treatment of GERD.Discovery of VU0431316: a negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety.Randomised clinical trial: effects of monotherapy with ADX10059, a mGluR5 inhibitor, on symptoms and reflux events in patients with gastro-oesophageal reflux disease.Localization of mGluR5, GABAB, GABAA, and cannabinoid receptors on the vago-vagal reflex pathway responsible for transient lower esophageal sphincter relaxation in humans: an immunohistochemical study.Recent Advances in the Pharmacological Management of Gastroesophageal Reflux Disease.Effect of rimonabant on oesophageal motor function in man.
P2860
Q26775243-FB7844FA-AC50-443A-8305-B88F27C1DBFBQ30448534-061D44A3-B6F4-41EF-9700-857D010413DEQ30448778-E2841D84-D59F-4EED-8AAC-DA86A7072042Q30464619-CADBCE0E-E205-4108-A8B3-A4607CE916A4Q33695362-3695E235-E6C9-43C2-8C25-F79554E2DFAFQ33936309-52AA9E81-C848-4733-9DD4-E63650852A79Q34001216-42054D04-F2E5-40EB-91AE-FA9DEAF018AEQ34373958-45D9730B-27C5-4A21-9E3C-2706E1610A78Q34468639-17BF4117-5028-4BA1-85AC-66E18ABF4E5BQ34734351-37748F03-EF2B-4DBC-BDC9-E50E702365F9Q35210746-0C9708CD-3273-44EE-BF4B-B425FABD6B10Q35657336-E0202B4C-FF8F-43B8-A3E8-72BF00DEE454Q35738179-248010DC-9593-4B20-9361-666CCCAF5FE2Q35952381-13897149-FD8F-436A-AF03-71DC01A3A297Q35999502-F304B94A-B4F0-411E-B7E3-435842E6B482Q37745066-A757E0BD-AD26-47B6-B1D3-E08D516E63FFQ37773480-FE7B894E-0188-44F6-B890-C13E72CEE231Q37827182-626B779B-6365-4DA5-A5A2-FE8E32955A4FQ37861794-A2BF1C1E-911D-4813-9084-CDA2D3469CCFQ37957701-32B64DC3-9437-496F-92B0-53CF770A3A73Q37959240-A9BF861B-2A1A-4759-866F-53ACD6FBA41BQ38001073-13717B84-5C16-44FC-8792-343EF4100E32Q38029727-F818D819-4BE2-4522-8303-3A0454974AFEQ38031832-CF247133-96B0-4A09-B58D-EF229118151EQ38057369-FBDAD4FD-093D-41BE-82A7-FC6AE99C36F8Q38075897-963BC713-2CB6-4D4C-BF5C-10A120052656Q38123482-431C5A40-BCF4-43CE-96E2-CBAA3DC83C7DQ38190016-27894359-7B03-42F6-9DCD-36D6D2B20B35Q38609120-096F1500-7201-4063-AB44-21F1D99E6E0FQ39455598-3BB308B5-FF5C-452F-873C-178130FFEAF4Q39682981-752279CD-7E90-48B3-8143-3BC0727A6EF2Q39783930-D21D62D2-4774-490F-BDD7-D267B067E463Q41891138-61CE01B8-BEB6-4F1D-9DF2-7D1C85BB5EC2Q41943753-1658E253-7370-4FAA-8CD5-752AE4607B2AQ42374441-94F40C0E-4CF1-4583-8063-4E2021AC3B18Q42728918-D66FB687-57EC-42B1-A246-3EC389987BF0Q48316933-F767D26F-0196-4E50-A595-C53734ABD8E5Q48704972-7F108B66-FB13-4BCB-9B10-FCBBA2C0875EQ50129556-75E98E6D-68AB-417A-9A5C-630F8AEE6A53Q51381392-6A20D0C7-FF70-426B-BFB5-7E411E6774C2
P2860
A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastro-oesophageal reflux disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A proof-of-concept study evalu ...... ro-oesophageal reflux disease.
@en
A proof-of-concept study evalu ...... ro-oesophageal reflux disease.
@nl
type
label
A proof-of-concept study evalu ...... ro-oesophageal reflux disease.
@en
A proof-of-concept study evalu ...... ro-oesophageal reflux disease.
@nl
prefLabel
A proof-of-concept study evalu ...... ro-oesophageal reflux disease.
@en
A proof-of-concept study evalu ...... ro-oesophageal reflux disease.
@nl
P2093
P2860
P356
P1433
P1476
A proof-of-concept study evalu ...... ro-oesophageal reflux disease.
@en
P2093
P2860
P304
P356
10.1136/GUT.2008.162040
P407
P577
2009-05-20T00:00:00Z